Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder

World J Urol. 2000 Dec;18(6):439-43. doi: 10.1007/pl00007088.


Current pharmacological treatment modalities for urge incontinence and low compliance bladder are limited by a low clinical efficacy and the significant side effects of the standard drugs available. Previous in vitro studies indicated a possible functional relevance of the intracellular phosphodiesterase (PDE)-1 isoenzyme in the regulation of human detrusor smooth muscle contractility. We therefore investigated the effect of the PDE-1 inhibitor vinpocetine in nonresponders to standard pharmacological therapy. In 11/19 patients (57.9%) clinical symptoms and/or urodynamic parameters were improved. Although these initial data are preliminary, they represent the first evidence that isoenzyme-selective PDE inhibition may be a novel approach to the treatment of lower urinary tract disorders.

Publication types

  • Clinical Trial

MeSH terms

  • Compliance
  • Female
  • Humans
  • Isoenzymes / antagonists & inhibitors*
  • Male
  • Middle Aged
  • Phosphodiesterase Inhibitors / adverse effects
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Phosphoric Diester Hydrolases / drug effects*
  • Pilot Projects
  • Urinary Bladder / physiopathology
  • Urinary Bladder Diseases / drug therapy*
  • Urinary Bladder Diseases / physiopathology
  • Urinary Incontinence / drug therapy*
  • Urinary Incontinence / physiopathology
  • Urodynamics
  • Vinca Alkaloids / adverse effects
  • Vinca Alkaloids / therapeutic use*


  • Isoenzymes
  • Phosphodiesterase Inhibitors
  • Vinca Alkaloids
  • vinpocetine
  • Phosphoric Diester Hydrolases